20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
BioAge Labs, Inc (BIOA) operates in the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry and is headquartered in EmeryVille, United States with about 60 employees. Its market capitalization is roughly $269 million. In the fiscal year ended 2025-12-31, BIOA reported $9M in revenue and ($81M) in net income.
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging.
Interactive charts & full statements → Open the BIOA valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $10M | $9M | $0M | $0M | $0M | $15M | $8M | $2M | $2M | $3M |
| Gross Profit | $10M | $9M | — | — | — | ($7M) | ($5M) | $0M | ($5M) | $0M |
| Gross Margin % | 99.4% | 100.0% | — | — | — | -49.4% | -65.2% | -20.3% | -291.7% | -0.9% |
| Operating Income (EBIT) | ($106M) | ($93M) | ($78M) | ($48M) | ($40M) | ($110M) | ($30M) | ($39M) | ($35M) | ($41M) |
| Operating Margin % | -1026.3% | -1031.5% | — | — | — | -736.2% | -358.2% | -1773.9% | -2281.5% | -1545.1% |
| Net Income | ($94M) | ($81M) | ($71M) | ($64M) | ($40M) | ($98M) | ($22M) | ($37M) | ($46M) | ($33M) |
| Net Margin % | -912.2% | -896.1% | — | — | — | -656.8% | -271.7% | -1713.9% | -3008.4% | -1246.3% |
| EBITDA | ($94M) | ($80M) | ($69M) | ($56M) | ($39M) | ($89M) | ($13M) | ($33M) | ($45M) | ($39M) |
| Earnings Per Share (EPS) | $-2.39 | $-2.24 | $-1.98 | $-1.87 | $-1.16 | $-2.34 | $-0.66 | $-1.32 | $-1.65 | $-1.18 |
| Shares Outstanding (M) | 45M | 36M | 36M | 34M | 34M | 42M | 34M | 28M | 28M | 28M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $2M | $3M | $3M | $2M | $2M | $1M | $0M | $0M |
| Gross Profit | $2M | $3M | $3M | $2M | $2M | $1M | — | — |
| Gross Margin % | 100.0% | 97.7% | 100.0% | 100.0% | 100.0% | 100.0% | — | — |
| Operating Income (EBIT) | ($29M) | ($25M) | ($28M) | ($23M) | ($25M) | ($16M) | ($25M) | ($25M) |
| Operating Margin % | -1196.8% | -915.4% | -923.4% | -1126.6% | -1027.0% | -1133.4% | — | — |
| Net Income | ($26M) | ($22M) | ($26M) | ($20M) | ($22M) | ($13M) | ($21M) | ($23M) |
| Net Margin % | -1064.8% | -802.8% | -842.8% | -982.0% | -894.0% | -891.0% | — | — |
| EBITDA | ($26M) | ($22M) | ($26M) | ($20M) | ($21M) | ($13M) | ($21M) | ($23M) |
| Earnings Per Share (EPS) | $-0.58 | $-0.52 | $-0.72 | $-0.56 | $-0.60 | $-0.36 | $-0.59 | $-0.68 |
| Shares Outstanding (M) | 45M | 42M | 36M | 36M | 36M | 36M | 36M | 34M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($88M) | ($82M) | ($52M) | ($37M) | ($36M) | ($30M) | ($38M) | ($32M) | ($22M) | ($28M) |
| Capital Expenditures (CapEx) | $0M | $1M | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $13M |
| Free Cash Flow (FCF) | ($88M) | ($82M) | ($52M) | ($38M) | ($36M) | ($30M) | ($38M) | ($32M) | ($22M) | ($40M) |
| FCF Margin % | -850.7% | -915.5% | — | — | — | -199.3% | -454.7% | -1482.5% | -1455.1% | -1512.6% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($19M) | ($24M) | ($28M) | ($16M) | ($20M) | ($17M) | ($5M) | ($15M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($20M) | ($24M) | ($28M) | ($16M) | ($20M) | ($18M) | ($5M) | ($15M) |
| FCF Margin % | -799.2% | -868.4% | -921.5% | -782.2% | -834.5% | -1226.0% | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $397M | $295M | $358M | $26M | $28M | $70M | $161M | $143M | $152M | $114M |
| Cash & Cash Equivalents | $74M | $189M | $354M | $22M | $28M | $5M | $16M | $7M | $51M | $84M |
| Total Liabilities | $22M | $23M | $35M | $199M | $141M | $48M | $113M | $97M | $95M | $49M |
| Total Debt (Short + Long-Term) | $1M | $3M | $9M | $53M | $2M | $5M | $23M | $10M | $3M | $7M |
| Total Shareholders' Equity | $375M | $272M | $323M | ($173M) | ($113M) | $22M | $48M | $46M | $58M | $65M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive BIOA viewer.
About TickerBase · Data methodology & sources · Privacy · Terms